PharmaFocus Today – Page 79 – media

Notai Biotech’s Dry Mixed Suspension and Granule Production Lines Pass GMP Compliance Inspection

On January 21, Notai Biotech announced that the dry mixed suspension production line and granule production line in its Zhonghua Pharmaceutical Port factory (Workshop 203) recently received the “Drug GMP Compliance Inspection Notification” (Su Yao Jian Yao Sheng Gao [2025] 037 and [2025] 038) issued by the Jiangsu Provincial Drug Administration, passing the drug GMP compliance inspection. The workshop is designed according to FDA/EMA standards and has introduced first-tier international brand equipment, including Glatt’s wet granulation line, KILIAN’s double-outlet tablet press, SYNTEGON’s capsule filling machine, Glatt’s coating machine, and CAM’s automated packaging line. The designed annual production capacities are 4.5 billion tablets & hard capsules, 36 million bottles of oral dry mixed suspensions & granules, and 450 million bags of granules/powders. The workshop has passed completion acceptance. Notai Biotech stated that the successful GMP compliance inspection of the dry mixed suspension and granule production lines indicates that the production lines ...
- Source: drugdu
- 144
- January 25, 2025
4 types of “peripheral vascular intervention consumables” centralized procurement quotation completed

Hebei Province has launched the four types of peripheral vascular interventional medical consumables alliance centralized procurement rules four quotation work, and the quotation has been completed recently. 4 types of interventional consumables, recently completed quotation On January 16th, the Hebei Provincial Medical Drug and Equipment Centralized Procurement Center issued a notice on the implementation of the four pricing rules for the centralized and quantity based procurement of four types of medical consumables, including peripheral vascular intervention guidance pathways, in the inter provincial alliance. The notice also includes a list of companies that provide pricing for rule four, and requires them to complete the pricing for rule four. (Read the original text to obtain the list and original file) According to the previously released procurement documents, Rule Four is as follows: (1) After executing the selected rule three, enable the selected rule four, and the selected enterprise in rule four will ...
- Source: drugdu
- 141
- January 23, 2025
Shinva Medical, selling again

At the beginning of 2025, news of Shinva Medical once again came of selling hospitals. According to the “Shandong Finance Headlines” report, Shandong Shinva Medical Equipment Co., Ltd. (referred to as “Shinva Medical”, 600587. SH) has officially listed and transferred 55% equity of its subsidiary, Shandong Xinhua Changguo Hospital Investment Management Co., Ltd. (referred to as “Xinhua Changguo” or “the target company”), for a transfer price of 113 million yuan. 01. Stripping off private hospitals for second-class epilepsy Xinhua Changguo, which was officially listed and transferred by Shinva Medical, was established in 2012 with a registered capital of 120 million yuan. It mainly engages in investments in the pharmaceutical and medical service industries. Its wholly-owned subsidiary, Zibo Changguo Hospital (referred to as “Changguo Hospital”), is a privately-owned hospital specializing in epilepsy diagnosis, treatment, and traditional Chinese medicine preparations for epilepsy. When the hospital opened, the media reported that Changguo Hospital ...
- Source: drugdu
- 147
- January 23, 2025
Trump announces the withdrawal of the United States from the World Health Organization; Watson Biotech’s clinical research application for the 20 valent pneumonia vaccine has been accepted | early participation in pharmaceutical research

NO.1 WHO responds to Trump’s announcement of ‘withdrawal’: hopes the United States will reconsider On January 21st, according to CCTV News, US President Trump signed an executive order announcing the US withdrawal from the World Health Organization. The World Health Organization expressed regret over President Trump’s announcement on his first day in office that the United States would withdraw from the organization. The WHO said that WHO plays a vital role in protecting the health and safety of people around the world, including Americans. The World Health Organization hopes that the United States will reconsider and engage in constructive dialogue with the new US government to maintain the partnership between the United States and the World Health Organization, benefiting the health and well-being of millions of people worldwide. Commentary: The news of the United States’ decision to withdraw from the World Health Organization has attracted widespread attention and concern worldwide, ...
- Source: drugdu
- 204
- January 23, 2025
Trump ‘returns’, CXO’s top brother’ sharp sword ‘hanging high

On January 20th Eastern Time, President elect Trump will hold his inauguration ceremony, and the highlight of the ceremony – Trump’s swearing in ceremony and inauguration speech – will take place at 12 noon Eastern Time (i.e. 1 am Beijing Time on January 21st), at which time Trump will officially begin his second presidential term. According to media reports, during a two-hour meeting with Senate Republicans, Trump stated that he has prepared about 100 executive orders and plans to sign them on his first day of office on January 20, 2025. These administrative orders may involve multiple sensitive areas such as tariffs and borders, and will set the tone for the global financial market. Since Trump nominated “vaccine skeptic” Robert Kennedy Jr. as the next Secretary of Health and Human Services last month, the US pharmaceutical industry has been shrouded in gloom. In September of this year, Kennedy Jr. published ...
- Source: drugdu
- 178
- January 23, 2025
Survival VS making money! BeiGene will make a profit, Junshi will reduce losses, Chinese medicine and vaccines will decline by 60%, and hundreds of pharmaceutical companies will lose 9 billion?

With the end of 2024, A-shares have also entered the stage of announcing full-year performance. According to statistics from E-Pharmaceutical Manager, as of January 20, in the biopharmaceutical industry, a total of 101 A-share listed companies and 7 Hong Kong-listed companies disclosed performance forecasts. The drama of the strong getting stronger is still being staged in each sub-sector. The Chinese medicine sector, such as Dong-E-E-Jiao, is not only expected to win a net profit of 1.5 billion to 1.6 billion yuan, but also an increase of 30% to 39%; the net profit of the Science and Technology Innovation Board listed company Sansheng Guojian is expected to be 700 million to 712 million yuan, an increase of 137.73% to 162%. In addition, Sinopharm Modern, a chemical pharmaceutical company, Tebao Bio, a biological product company, Synthetic Biology leader Chuan Ning Bio, and orthopedic consumables leader Dabao Medical have also achieved a “double ...
- Source: drugdu
- 126
- January 23, 2025
Net profit attributable to parent company expected to drop by 57% to 67% in 2024

On January 20, 2025, WALVAX, a leading vaccine company in the A-share market, issued an announcement that its operating income is expected to be about 2.86 billion yuan, a sharp drop from 4.114 billion yuan in the same period last year; it is expected that the net profit attributable to parent company in 2024 will be 140 million to 180 million yuan, a decrease of 57% to 67% from 419 million yuan in the same period last year. Net profit after deducting non-recurring gains and losses is expected to be 110 million to 150 million yuan, a decrease of 74% to 81% from 574 million yuan in the same period last year. WALVAX disclosed that the main reasons for the performance changes include: the decline in sales revenue due to the decline in the number of newborns in China and the intensification of market competition. At the same time, in ...
- Source: drugdu
- 124
- January 23, 2025
Nat Immunol | Mechanisms of Durability of Vaccine Antibody Responses

In vaccinology, inducing durable protective immunity is a major challenge. It is generally believed that protection against infection is mainly achieved through antibodies, which prevent host cells from becoming infected. Some live attenuated vaccines (such as smallpox and yellow fever vaccines) induce durable antibody responses that can last a lifetime; however, in other types of vaccines, including inactivated subunit vaccines for seasonal influenza, pertussis vaccines, Salmonella typhi, Neisseria meningitidis vaccines, as well as RTS,S malaria vaccines and some candidate vaccines against HIV, the phenomenon of waning antibody responses has been widely documented. Why some vaccines provide lifelong protection while others only protect for a few months remains a major unsolved mystery in immunology. An adjuvant is a component of a vaccine that enhances the strength and durability of the immune response. For more than 70 years, insoluble aluminum salts (alum) have been the only approved adjuvants. However, the number of ...
- Source: drugdu
- 131
- January 23, 2025
Six new drugs will be launched this year, aiming for 20 billion yuan

Innovent Biologics also disclosed multiple drug collaborations and research and development progress on the eve of the conference. Although it did not disclose a time signal to turn losses into profits, it also stated at the conference that its confidence in achieving a domestic product revenue target of 20 billion yuan by 2027 has become increasingly firm based on the upcoming commercialization of multiple drugs. On the morning of January 17th, Innovent Biologics announced the disclosure of its newly introduced third-generation EGFR-TKI lung cancer targeted drug, Aoyi Xin ® (Lirotinib tablets) have been approved for marketing by the National Medical Products Administration. In the early morning of the same day, Yu Dechao, the founder, chairman, and CEO of Innovent Biologics, revealed at the JPM2025 conference that six new drug varieties will be launched in 2025, including three heavyweight products, Masidomide, Pitacizumab, and Tetuximab; We plan to submit new drug applications ...
- Source: drugdu
- 246
- January 22, 2025
Two innovative medical devices enter the special review process

According to the China Medical Device Innovation and Priority Approval Database, two innovative medical devices have entered the special review process in recent public announcements released by local drug regulatory authorities across the country. They are respectively the exercise rehabilitation system of Beijing Tianxing Medical Co., Ltd. (hereinafter referred to as Tianxing Medical) and the disposable angle guided puncture needle of Jiangsu Chunzhen Medical Technology Co., Ltd. (hereinafter referred to as Chunzhen Medical). Tianxing Medical, a leading domestic enterprise in sports medicine Tianxing Medical was founded in 2017 and is a leading domestic enterprise in sports medicine, committed to providing comprehensive clinical solutions for sports medicine. Its products are used in sports medicine equipment, implants, and surgical instruments for shoulder joints, knee joints, foot/ankle joints, hip joints, elbow joints, and hand/wrist joints, with a total of more than 300 specifications approved by NMPA. They have been clinically applied in thousands ...
- Source: drugdu
- 201
- January 22, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.